Founded in 2012, OncoDNA set out to improve outcomes for patients with late-stage disease. By combining its deep subject matter expertise with advanced molecular tools, the OncoDNA team generates a detailed report for oncologists that describes each patient’s tumor.
Over the past decade, OncoDNA has refined its approach, optimizing for scale, accuracy, and information density. One such refinement included the adoption of targeted sequencing with Twist reagents. We recently spoke with Koenraad Eycken, Chief Product Officer at OncoDNA, to learn more about the company’s evolution and how their collaboration with Twist is helping hospitals around the world.